Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

中国泰凌医药集团
CHINA NT PHARMA GROUP

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 01011)

NOTICE OF BOARD MEETING
AND
UPDATE OF PUBLICATION OF ANNUAL RESULTS

Reference is made to the announcement of China NT Pharma Group Company Limited (the "**Company**") dated 13 March 2020 in relation to the meeting of the board of directors (the "**Board**") held on Friday, 27 March 2020 and the unaudited annual results announcement of the Company dated 27 March 2020.

The Company's business segments are substantially based in the People's Republic of China (the"**PRC**") and due to the travel and quarantine restrictions in the PRC arising from the coronavirus disease (COVID-19) pandemic, the audit process for the Company's financial results for the year ended 31 December 2019 has been affected.

The Company hereby announces that another meeting of the Board will be held on Thursday, 9 April 2020 in Hong Kong, for the purposes of, inter alia, considering and approving the audited annual results of the Company and its subsidiaries for the year ended 31 December 2019 and its publication.

By order of the Board
China NT Pharma Group Company Limited
Ng Tit
Chairman

Hong Kong, 30 March 2020

As at the date of this announcement, the executive directors of the Company are Mr. Ng Tit, Ms. Chin Yu and Mr. Wu Weizhong; the non-executive director of the Company is Dr. Qian Wei; and the independent non-executive directors of the Company are Mr. Tze Shan Hailson Yu, Mr. Pan Fei and Dr. Zhao Yubiao.